zation
report
death
case
laboratoryconfirm
infect
avian
influenza
southeast
asia
europ
africa
januari
march
instanc
humantohuman
transmiss
viru
appear
occur
suggest
viru
potenti
caus
influenza
pandem
furthermor
viru
resist
oseltamivir
isol
vietnames
girl
virus
isol
individu
hong
kong
found
resist
interferon
tumornecrosi
factora
develop
vaccin
thu
prioriti
effort
prevent
human
pandem
influenza
recent
shown
combin
poli
c
synthet
doublestrand
rna
intranas
vaccin
splitproduct
viru
vaccin
either
strain
strain
protect
mice
infect
avirul
highli
pathogen
influenza
viru
poli
c
howev
poor
safeti
profil
poli
poli
c
u
ampligen
structur
similar
doublestrand
rna
exhibit
safe
profil
doubleblind
placebocontrol
phase
clinic
trial
administ
intraven
dose
averag
dose
mg
human
preliminari
observ
indic
adjuv
ampligen
also
protect
effect
influenza
virus
furthermor
intranas
inocul
either
formalininactiv
vaccin
adenoviru
vectorbas
influenza
vaccin
protect
mice
lethal
heterolog
viru
takada
et
al
report
intranas
inocul
formalininactiv
viru
vaccin
strain
high
dose
protect
mice
infect
heterolog
viru
find
led
us
examin
whether
intranas
inocul
ampligen
trival
inactiv
influenza
vaccineanewcaledonia
present
report
demonstr
intranas
inocul
current
trival
inactiv
influenza
vaccin
combin
ampligen
mucos
adjuv
elicit
protect
immun
strain
ahongkong
isol
morerec
isol
significantli
improv
surviv
rate
challeng
viru
result
studi
suggest
crossprotect
immun
induc
vaccin
mediat
mucos
immun
respons
like
secretori
iga
antibodi
specif
influenzaviru
protein
femal
balbc
mice
week
old
purchas
japan
slc
kept
specificpathogenfre
condit
virus
wildtyp
strain
use
present
studi
viru
isol
patient
fatal
influenza
prepar
mardindarbi
canin
kidney
mdck
cell
without
special
step
adapt
mice
viru
viru
propag
embryon
chicken
egg
day
virus
store
viru
titer
quantifi
plaqu
assay
use
mdck
cell
inocul
viral
challeng
mice
anesthet
diethyl
ether
inocul
time
consecut
interv
week
either
intranas
subcutan
mg
trival
vaccin
mg
vaccin
strain
without
mg
ampligen
accord
modif
procedur
describ
elsewher
mous
micegroup
anesthet
subject
infect
inocul
ml
viru
suspens
pfu
pb
nostril
mlnostril
day
final
inocul
pfu
correspond
time
mous
lethal
dose
avietnam
strain
infect
model
anim
experi
perform
accord
guid
anim
experi
perform
nation
institut
infecti
diseas
niid
approv
anim
care
use
committe
niid
infect
viru
perform
biosafeti
level
contain
approv
niid
mice
euthan
anesthet
chloroform
nasalwash
serum
sampl
collect
measur
viru
titer
vaccinespecif
antibodi
elisa
determin
level
specif
iga
igg
antibodi
perform
describ
elsewher
plate
coat
either
trival
vaccin
splitproduct
viru
vaccin
ha
vaccin
use
vaccin
tabl
formalininactiv
viru
vaccin
deriv
recombin
avirul
avian
viru
contain
modifi
ha
neuraminidas
na
highli
pathogen
avian
influenza
strain
viral
protein
influenza
viru
tabl
hemagglutin
inhibit
hi
test
perform
receptordestroy
enzym
ii
denka
seiken
ad
red
blood
celltreat
serum
sampl
overnight
inactiv
nonspecif
hemagglutin
inhibitor
follow
incub
h
inactiv
receptordestroy
enzym
hi
test
perform
accord
microtit
method
sever
viru
titer
measur
plaqu
assay
use
mdck
cell
describ
elsewher
antigenspecif
cell
respons
antigenspecif
cell
respons
measur
describ
elsewher
spleen
remov
mice
day
third
vaccin
cell
purifi
singlecel
suspens
deplet
cell
use
concentr
interferon
ifn
g
cultur
supernat
measur
use
elisa
mous
cytokin
biosourc
intern
cell
prolifer
monitor
addit
h
thymidin
kbqwell
icn
biomed
h
cell
harvest
cell
harvest
onto
micropl
bond
gfb
filter
packard
instrument
incorpor
radioact
calcul
micropl
scintil
counter
packard
instrument
data
mean
sd
valu
independ
experi
perform
cell
micegroup
statist
data
present
mean
se
mean
sd
experiment
group
compar
use
student
test
pair
observ
consid
p
statist
signific
evalu
efficaci
ampligen
mucos
adjuv
trival
inactiv
influenza
vaccin
examin
iga
igg
respons
compon
strainsanewcaledonia
anewyork
bshanghaiin
mice
inocul
intranas
subcutan
mg
vaccin
without
mg
ampligen
high
concentr
iga
antibodi
ha
appar
nasalwash
sampl
mice
inocul
intranas
trival
vaccin
ampligen
tabl
contrast
mucos
iga
respons
observ
either
mice
inocul
intranas
trival
vaccin
without
ampligen
mice
inocul
subcutan
trival
vaccin
without
ampligen
compar
noninocul
mice
concentr
igg
antibodi
ha
serum
significantli
increas
mice
inocul
intranas
trival
vaccin
ampligen
mice
inocul
subcutan
trival
vaccin
without
ampligen
tabl
serum
igg
respons
induc
either
mice
inocul
intranas
vaccin
without
ampligen
mice
inocul
via
either
rout
ampligen
alon
hi
titer
regard
anewcaledonia
newyork
bshanghai
viru
strain
examin
vitro
use
serum
sampl
group
mice
antibodi
examin
serum
sampl
mice
inocul
subcutan
vaccin
without
ampligen
show
high
hi
activ
titer
wherea
serum
sampl
mice
inocul
intranas
ampligen
without
trival
vaccin
show
littl
respons
hi
titer
detect
serum
sampl
noninocul
mice
inocul
intranas
vaccin
without
ampligen
inocul
via
either
rout
ampligen
alon
next
character
crossreact
antibodi
respons
variou
group
inocul
mice
compar
noninocul
mice
concentr
iga
antibodi
nasalwash
sampl
significantli
increas
mice
inocul
intranas
trival
vaccin
ampligen
tabl
concentr
igg
antibodi
serum
also
significantli
increas
mice
inocul
intranas
trival
vaccin
ampligen
mice
inocul
subcutan
trival
vaccin
without
ampligen
tabl
hi
titer
regard
heterolog
ahongkong
viru
examin
vitro
use
serum
sampl
group
mice
antibodi
examin
howev
antibodi
show
appreci
crossneutr
activ
viru
strain
tabl
detect
hi
activ
anewcaledonia
newyork
bshanghai
ahongkong
viru
strain
nasalwash
sampl
inocul
mice
data
shown
lack
activ
like
due
dilut
antibodi
intrins
collect
nasalwash
sampl
also
examin
crossprotect
effect
ampligen
combin
trival
vaccin
mice
challeng
pfu
viru
noninocul
mice
viru
titer
pfuml
nasalwash
sampl
obtain
day
challeng
compar
noninocul
mice
nasalwash
sampl
mice
inocul
intranas
either
trival
vaccin
alon
ampligen
alon
mice
inocul
subcutan
trival
vaccin
ampligen
show
nonsignific
reduct
viru
titer
contrast
nasalwash
sampl
mice
inocul
intranas
trival
vaccin
ampligen
contain
detect
viru
tabl
nasalwash
serum
sampl
group
mice
test
abil
inhibit
hemagglutin
induc
virus
hi
activ
detect
nasalwash
serum
sampl
differ
inocul
group
data
shown
next
examin
whether
combin
trival
vaccin
ampligen
confer
crossprotect
heterolog
influenza
virus
includ
strain
figur
challeng
pfu
avietnam
viru
mice
inocul
trival
viru
ampligen
show
signific
reduct
viru
titer
compar
noninocul
mice
figur
furthermor
day
challeng
viru
intranas
inocul
mice
n
p
still
aliv
wherea
subcutan
inocul
mice
noninocul
mice
dead
n
p
n
p
subcutan
inocul
mice
show
typic
ruffl
fur
neurolog
symptom
tremor
spin
evidenc
moribund
mice
contrast
mice
challeng
viru
show
ruffl
fur
appear
healthi
challeng
pfu
viru
mice
inocul
trival
vaccin
ampligen
show
reduct
viru
titer
compar
noninocul
mice
figur
day
challeng
intranas
inocul
mice
still
aliv
wherea
subcutan
inocul
mice
n
p
noninocul
mice
die
final
chaln
p
leng
pfu
viru
mice
inocul
trival
vaccin
ampligen
show
signific
reduct
viru
titer
compar
noninocul
mice
figur
day
challeng
viru
intranas
inocul
mice
still
aliv
wherea
subcutan
inocul
mice
noninocul
mice
n
p
n
p
die
taken
togeth
result
indic
intranas
inocul
trival
vaccin
ampligen
effect
challeng
heterolog
influenza
viru
subcutan
inocul
next
examin
whether
intranas
inocul
trival
vaccin
without
ampligen
induc
cell
respons
either
homolog
viru
strain
heterolog
virus
day
final
inocul
cell
isol
spleen
vaccin
mice
cultur
irradi
antigenpres
cell
absenc
presenc
trivalentvaccin
compon
concentr
mgml
mgml
cell
mice
inocul
trival
vaccin
ampligen
prolifer
produc
ifng
manner
depend
concentr
trivalentvaccin
antigen
figur
howev
antigen
effect
prolifer
ifng
product
cell
isol
either
mice
inocul
trival
vaccin
alon
figur
noninocul
mice
figur
mice
intranas
inocul
trival
vaccin
ampligen
show
crossreact
cell
respons
wholeviru
antigen
figur
result
suggest
intranas
inocul
trival
vaccin
ampligen
induc
system
cell
respons
homolog
vaccin
strain
heterolog
viru
strain
evalu
immunogen
trival
inactiv
influenza
vaccin
ha
vaccin
prepar
season
crossprotect
efficaci
differ
influenza
virus
administ
either
alon
ampligen
compar
noninocul
mice
inocul
intranas
subcutan
trival
vaccin
ampligen
manifest
lower
viru
titer
nasalwash
sampl
day
challeng
influenza
viru
howev
wherea
intranas
inocul
effect
improv
surviv
rate
mice
infect
antigen
distinct
viru
strain
subcutan
inocul
specul
crossprotect
may
diat
mucos
immun
respons
probabl
via
secretori
iga
antibodi
viral
protein
elsewher
shown
polymer
immunoglobulin
receptorknockout
mice
secret
iga
show
less
crossprotect
efficaci
variant
influenza
viru
infect
challeng
either
influenza
viru
influenza
b
viru
howev
antiha
antina
antibodi
normal
act
neutral
antibodi
seem
contribut
crossprotect
none
nasalwash
serum
sampl
collect
inocul
mice
present
studi
exhibit
crossneutr
activ
vitro
tabl
antibodi
neutral
hi
activ
virus
whose
subtyp
respect
vaccin
strain
tabl
find
may
interpret
suggest
iga
antibodi
specif
viral
intern
protein
import
heterosubtyp
protect
secretori
iga
antibodi
may
neutral
viru
infect
transcytosi
infect
epitheli
cell
present
studi
intranas
inocul
trival
vaccin
ampligen
induc
system
cell
respons
homolog
viru
strain
heterolog
viru
strain
result
support
notion
heterolog
protect
achiev
inocul
larg
attribut
crossreact
secretori
iga
cross
protect
immun
seem
correl
viru
replic
noninocul
mice
although
noninocul
intranas
inocul
mice
challeng
titer
avietnam
viru
viru
titer
noninocul
mice
differ
everi
experi
find
explain
observ
differ
crossprotect
effect
tabl
figur
recent
studi
present
strong
case
use
doublestrand
rna
dsrna
adjuv
intranas
vaccin
dsrna
power
tolllik
receptor
agonist
induct
innat
immun
respons
particularli
signific
appar
abil
adjuv
broaden
rang
viral
mutant
strain
wildtyp
vaccin
provid
full
partial
protect
properti
becom
increasingli
import
new
strain
influenza
viru
appear
ever
increas
frequenc
exhibit
potenti
evolv
global
pandem
limit
approach
tradit
dsrna
experiment
agent
approv
human
use
andor
exhibit
signific
toxic
ie
case
polyi
polyc
human
clinic
trial
one
except
dsrna
product
ampligen
polyi
polyc
u
ampligen
studi
patient
cumul
system
drug
exposur
dose
ampligen
complet
pivot
phase
iiiii
trial
chronic
fatigu
syndrom
excel
safeti
record
human
summari
intranas
inocul
trival
inactiv
influenza
vaccin
ampligen
induc
crossprotect
mucos
immun
heterolog
influenza
viru
mice
intranas
inocul
annual
influenza
vaccin
ampligen
may
thu
repres
strategi
human
gener
protect
mucos
immun
newli
emerg
highli
pathogen
avian
influenza
virus
dr
u
suzuki
komas
kitasato
institut
saitama
japan
provid
us
vaccin
